Address: 50 Soldiers Field Place, Boston, MA 02135 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
RG001 tablet is a new SHP2 allosteric inhibitor independently developed by Ringene based on structural biology and drug metabolism-oriented drug design methods. Medicilon provides a range of preclinical services from drug targets to IND filing in the development of RG001 tablets to enter the clinical trial phase, including drug discovery, pharmaceutical research, and pre-clinical research (drug efficacy and safety evaluations).
ABM Therapeutics has cooperated with Medicilon since 2016. During this time, Medicilon FTE helped ABM Therapeutics discover the clinical candidate compound (PCC) ABM-1310 (the drug is currently undergoing clinical trials in China and the United States in parallel).
MindRank, is an AI pharmaceutical company. In the cooperation with Medicilon’s FTE, it has utilised the advantages of AI design combined with laboratory confirmation. In a short-term, low-cost and high-efficiency working mode, Medicilon completed the cooperative project with high quality, and was awarded the "2021 Excellent Team Award" by the customer.